Table 2 FDA-approved drugs for glioblastoma
Drug name (brand name) | Drug type (PubChem CID) | Cancer treatment | Mechanism of action | Route of administration |
|---|---|---|---|---|
Bevacizumab (Avastin, Mvasi, Zirabev, Alymsys, Avzivi, Vegzelma) | Monoclonal antibody | Glioblastoma, cervical cancer, CRC, HCC, non-squamous NSCLC, RCC, EOC, FTC, PCC | Binds to VEGFR, resulting in prevention of new blood vessel formation, reduction of tumor vasculature, and reduction of tumor blood supply | Intravenous |
Carmustine (BiCNU) | Small molecule (2578) | Glioblastoma and other brain tumors, HL, MM, NHL | Cross-linking of DNA and RNA, resulting in inhibition of DNA synthesis, RNA production and RNA translation | Intravenous |
Lomustine (CeeNU, Gleostine) | Small molecule (3950) | Glioblastoma and other brain tumors, HL | A reactive metabolite alkylating agent causes alkylation and cross-linking of DNA and RNA | Oral |
Temozolomide (Temodar) | Small molecule (5394) | Glioblastoma multiforme, anaplastic astrocytoma | Prevents cancer cells from making DNA, leading to cell cycle arrest at G2/M and apoptosis | Oral or intravenous |
Vorasidenib (Voranigo) | Small molecule (117817422) | Astrocytoma, oligodendroglioma | Inhibits IDH1 and IDH2 mutants, resulting in reduced production of the oncometabolite D2HG and partial restoration of cell differentiation | Oral |
